Prof. Lixiang Liu et al. published in the European Heart Journal the results of a subgroup analysis of the FEVER study with Chinese characteristics, in which an intensive antihypertensive regimen combining low-dose diuretics and felodipine to reduce systolic blood pressure <140 mmHg reduces events and benefits those >65 years of age. A subgroup analysis of the FEVER study by Professors Lixiang Liu and Yuqing Zhang from the Fu Wai Cardiovascular Hospital showed a significant cardiovascular benefit from a systolic BP reduction of <140 mmHg in class I (systolic <153 mmHg) or elderly (>65 years) hypertensive patients without comorbidities, which supports the current guideline recommendation of a systolic BP reduction of <140 mmHg in all hypertensive patients. 140 mmHg in all hypertensive patients" provides strong evidence to support the current guideline recommendation. （The FEVER study is a double-blind, randomized study of felodipine that included 9711 Chinese subjects. The results showed that low-dose hydrochlorothiazide combined with low-dose felodipine (intensive antihypertensive therapy) significantly reduced the risk of cardiovascular events (25%-35%) compared with low-dose hydrochlorothiazide + placebo therapy (usual antihypertensive therapy), with mean systolic blood pressure decreasing to 142 mmHg and 138 mmHg in the two groups. however, the FEVER study did not group subjects according to age and However, the FEVER study did not group subjects according to their age and comorbidities. The investigators grouped subjects in the FEVER study according to sex, systolic blood pressure level, age, smoking status, total plasma cholesterol level, presence of combined left ventricular hypertrophy, simple systolic hypertension and diabetes mellitus, and history of cardiovascular disease. The primary endpoint of the study was time to first stroke, and the secondary endpoints were time to first cardiovascular event, cardiac event, all-cause death, and cardiovascular disease death. The investigators used Cox regression models to assess differences in endpoint events among the different subgroups of subjects. The results showed that the mean systolic blood pressure was <140 mmHg and >140 mmHg in the intensive antihypertensive group and in the regular antihypertensive group, respectively, and that the risk of stroke events was significantly reduced in the intensive antihypertensive treatment group by 39%, 29%, and 44% for patients with no comorbidity, class I, and elderly hypertension, respectively. In addition, the risk of cardiovascular events and all-cause mortality was significantly lower in all 3 groups (29% to 47%, P=0.02 or <0.001). Over a mean follow-up period of 3.3 years, a reduction in mean systolic blood pressure of a few mmHg prevented 1.6, 1.1, and 3.8 stroke events and 2.1, 1.6, and 5.2 cardiovascular events per 100 patients with uncomplicated, elderly, or class I hypertension, in that order. The investigators noted that the evidence for a benefit of systolic blood pressure <140 mmHg in patients with uncomplicated hypertension or class I hypertension has been insufficient; in previous studies, the target value for lowering blood pressure in elderly hypertensive patients has almost always been 150 mmHg rather than 140 mmHg. The present study confirms the cardiovascular benefit of systolic blood pressure <140 mmHg in this population and provides strong evidence to support current guidelines. The present study confirms the cardiovascular benefit in these populations with systolic blood pressure <140 mmHg, providing strong evidence to support current guidelines.